---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Mechanism of action"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Mechanism of action. Topics: Allosteric insulin receptor antibody acting in liver, fat, and muscle; Selective and reversible reduction of insulin binding and signaling; Modulation without blocking insulin binding; Action on insulin and IGF-2 in both tumor types; 4 further topics. 8 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Allosteric insulin receptor antibody acting in liver, fat, and muscle

> “Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle.”
> “The antibody down modulates insulin receptor activity, thereby helping to restore glucose to a more normalized range in conditions associated with elevated insulin or insulin-like substances (e.g. IGF-2 variants).”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.1.2.6.1-2"></a>

### Selective and reversible reduction of insulin binding and signaling

> “The activity of insulin on target tissues is mediated by insulin receptor signaling, which causes increased glucose uptake into tissues, glycogen synthesis, suppression of gluconeogenesis, and suppression of free fatty acids and ketones ( 9 , 10 ).”
> “Ersodetug, a fully human insulin receptor–modulating antibody, engages an allosteric site on the insulin receptor to selectively and reversibly reduce insulin binding and signaling in a dose-dependent manner, leading to reduced insulin signaling ( 11 , 12 ).”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.1.2.6.1-3"></a>

### Modulation without blocking insulin binding

> “Insulin receptor modulating monoclonal antibody (IgG2)”
> “Allosterically binds to the insulin receptor in target tissue”
> “Does NOT block insulin binding”
> “Modulates insulin binding and signaling resulting in reduced glucose uptake from the bloodstream”

Source: [ENDO Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/ENDO_2026_ORF10_sunRIZE_Demirbilek_13June.pdf)

<a id="topic-2.1.2.6.1-4"></a>

### Action on insulin and IGF-2 in both tumor types

> “Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

> “The therapeutic potential of RZ358 in this setting was anticipated given that ICTH is mediated by insulin and that RZ358 is known to work at the insulin receptor to decrease excess insulin binding and activity.”
> “However, it was unknown if RZ358 would have utility in NICTH where hyperinsulinism is mediated by hormones such as insulin-like growth factor-2 (IGF-2) or its variants, which likewise cause hypoglycemia by binding to and activating the insulin receptor.”

Source: [Rezolute NICTH validation release (2024)](https://ir.rezolutebio.com/news/detail/327/rezolute-reports-validation-of-the-potential-use-of-rz358-for-treatment-of-non-islet-cell-tumor-hypoglycemia-nicth)

<a id="topic-2.1.2.6.1-5"></a>

### Action downstream from the source of insulin

> “Because ersodetug acts downstream from the pancreas, it has the potential to be universally effective at treating hypoglycemia due to any congenital or acquired form of HI.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-2.1.2.6.1-6"></a>

### Negative allosteric modulation: first-in-human publication

> “XOMA 358 (X358) is a fully human monoclonal antibody to the insulin receptor that acts as a negative allosteric modulator of insulin signaling.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-2.1.2.6.1-7"></a>

### Identity of the discovery antibody XMetD with XOMA 358

> “For this purpose we employed XMetD [also known as XOMA358 (X358)], a human anti-INSR IgG2 monoclonal antibody, discovered by XOMA (US) LLC.”

Source: [Patel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6150619/)

<a id="topic-2.1.2.6.1-8"></a>

### Reduced insulin affinity and signaling efficacy: discovery studies of XMetD

> “Addition of insulin reduced the affinity of XMetD to the INSR by 3-fold, and XMetD reduced the affinity of the INSR for insulin 3-fold.”
> “In addition to inhibiting INSR binding, XMetD also inhibited insulin-induced INSR signaling by 20- to 100-fold.”
> “These data indicated that XMetD was an allosteric antagonist of the INSR because, in addition to inhibiting the INSR via modulation of binding affinity, it also inhibited the INSR via modulation of signaling efficacy.”

Source: [Corbin et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3929448/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
